JENA, Germany and SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- SIRS-Lab
GmbH entered into a collaboration agreement with the U.S.-based bio-medical
company, Biosite(R) Incorporated (Nasdaq: BSTE) for the evaluation and
potential commercialization of sepsis markers.
Under the collaboration, SIRS-Lab will provide access to selected
biomarkers for sepsis. Biosite will then make antibodies to those selected
targets using the Company's proprietary antibody development process, which
combines immunization of mice and phage display to generate highly diverse
libraries of Omniclonal(R) antibodies with high affinity and low
cross-reactivity. The antibodies will be used to generate assays for the
measurement of the selected biomarker targets in blood samples. Validated
biomarkers will then be assessed for commercialization potential, with
high-value markers added to Biosite's product development process.
"We are delighted to work with Biosite to evaluate the potential value of
our sepsis biomarkers for clinical diagnostic applications," said Dr. Stefan
Rubwurm, SIRS-Lab's chief executive officer. "This agreement combines the
strengths of both companies: Biosite's proven antibody development and
commercialization process for diagnostic products with our expertise in
molecular medicine concerning inflammatory diseases."
"Our Biosite Discovery program is focused on diseases for which rapid and
accurate diagnostic tests are needed. Our antibody technology allows us to
quickly and economically evaluate potential biomarkers for new tests," said
Gunars Valkirs, Ph.D., senior vice president Biosite Discovery. "We value
SIRS-Lab's competence in the identification of biomarkers and we are pleased
to have access to their intellectual property in the area of sepsis."
The financial terms of the agreement were not disclosed.
About SIRS-Lab
SIRS-Lab, a research driven diagnostics company located in the
BioInstrumentation Center in Jena/Germany, is focused on the identification,
development and commercialization of novel, proprietary biomarkers. Those
biomarkers provide a basis for the development of diagnostic systems for the
early identification of inflammatory/ immunological host responses as well as
for the early identification of the bacterial causes of infection. SIRS-Labs
mission is the development of new diagnostic systems for clinical routine
diagnostic and therapy monitoring of sepsis and acute inflammatory diseases.
Information on SIRS-Lab can be found at http://www.sirs-lab.com/.
About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis. The
Company's products contribute to improvements in medical care by aiding
physicians in the diagnosis of critical diseases and health conditions.
Biosite's Triage(R) rapid diagnostics are used in approximately 50 percent of
U.S. hospitals and in more than 50 international markets. Information on
Biosite can be found at http://www.biosite.com.
Except for the historical information presented herein, matters discussed
in this press release are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including but not
limited to statements that are preceded by, followed by, or that include the
words "will"; "believes"; "should"; "intends"; "anticipates"; "plans";
"expects"; "estimates"; or similar statements are forward-looking statements.
Forward looking statements include statements about the potential benefits of
the collaboration and license agreement between Biosite and SIRS-Lab,
Biosite's ability to generate antibody libraries of selected targets and
evaluate the diagnostic utility of the targets, Biosite's ability to develop
and commercialize potential products based on selected targets and Biosite's
ability to incorporate any licensed targets into its product development
pipeline. Risks that should be considered include risks and uncertainties
regarding the discovery and product development process generally, risks
associated with the introduction of competitive products from companies with
greater capital and resources, uncertainties around the proprietary nature of
the targets subject to the collaboration, expansion or development of a direct
sales effort in domestic and international markets, and risks and expenses
associated with litigation, contract disputes, patent conflicts, product
recalls, manufacturing constraints, backlog, delays or inefficiencies,
shipment problems, seasonal customer demand, the timing of significant orders,
changes in reimbursement policies, regulatory changes, competitive pressures
on average selling prices, and the other risks detailed in Biosite's most
recent Annual Report on Form 10-K, as amended, Quarterly Report on Form 10-Q,
and other SEC filings. Biosite disclaims, any intent or obligation to update
these forward-looking statements. Copies of Biosite's public disclosure
filings are available from its investor relations department.
Biosite(R), Omniclonal(R), Triage(R) and New Dimensions in Diagnosis(R)
are registered trademarks of Biosite Incorporated. The Company's logo is a
trademark of Biosite Incorporated.
SOURCE Biosite Incorporated
 back to top
Related links:
http://www.biosite.com
Company News On-Call:
http://www.prnewswire.com/comp/116737.html
CONTACT:
Roberto C. Wolfer, Manager Business
Development, SIRS-Lab GmbH, +49-0-3641-508-250, or cell,
+49-0-179-788-5452, wolfer@sirs-lab.de, or Nadine Padilla VP,
Corporate & Investor Relations, Biosite Incorporated,
+1-858-805-2820, npadilla@biosite.com
|
